Poor correspondence between clinical and pathologic staging in stage 1 non-small cell lung cancer

Results from CALGB 9761, a prospective trial

Jonathan D'Cunha, James E. Herndon, Debra L. Herzan, G. Alexander Patterson, Leslie J. Kohman, David H. Harpole, Kemp H. Kernstine, Jeffrey A. Kern, Mark R. Green, Michael A. Maddaus, Robert A. Kratzke

Research output: Contribution to journalArticle

69 Citations (Scopus)

Abstract

Purpose: A major problem with the staging system for non-small cell lung cancer (NSCLC) is clinical underestimation of the extent of disease. Many patients with clinical stage 1 disease do not retain that designation following surgical resection. Herein, we present data from Cancer and Leukemia Group B (CALGB) protocol 9761 evaluating the correspondence between clinical and pathologic analysis in early stage NSCLC. Methods: Five hundred and two patients with suspected or biopsy-proven NSCLC classified as clinical stage 1 (T1-2, N0) by computed tomography (CT) scan or cervical mediastinoscopy were prospectively enrolled in CALGB 9761. The purpose of CALGB 9761 was to prospectively evaluate molecular markers of micrometastatic disease in stage 1 NSCLC. Enrollment occurred at 11 selected institutions within the CALGB. Patients with clinically suspected resectable early stage lung cancer were eligible for enrollment if they had no evidence of mediastinal or hilar adenopathy on CT scan or if they had CT evidence of potential N2 or N3 disease (lymph node ≥1.0 cm) but with negative mediastinoscopy. No prior chemotherapy or radiotherapy was permitted. Results: Of the 502 patients felt to have clinical stage 1 NSCLC enrolled in CALGB 9761, 489 underwent resection with complete surgical staging and routine histopathologic analysis. From these 489 patients, only 422 (86.3%) turned out to have pathologically documented NSCLC. Of these 422 patients, 302 (71.6%) had pathologic stage 1 disease (173 stage 1A and 129 stage 1B). Despite clinical assessment of stage 1 disease, 59 (14%) patients had pathologic stage 2 disease, 57 (13.5%) had stage 3 disease, and four (0.9%) patients had stage 4 disease. Of the patients undergoing resection for clinical stage 1 NSCLC, 65 patients did not have NSCLC (44 had benign disease and 21 had malignancies other than NSCLC) and two additional patients had dual synchronous primary NSCLC tumors and were not eligible for the study. Overall, only 61.7% (302 of 489) of patients with suspected stage 1 NSCLC disease retained that stage and diagnosis after complete surgical staging, while 38.3% had an inaccurate pre-operative clinical stage or diagnosis. Conclusions: The results from this prospective trial demonstrate the poor predictive value of current clinical staging techniques in early stage NSCLC. These findings will serve as a benchmark for comparison of future clinical imaging modalities and other tests evaluating early stage NSCLC.

Original languageEnglish (US)
Pages (from-to)241-246
Number of pages6
JournalLung Cancer
Volume48
Issue number2
DOIs
StatePublished - May 2005

Fingerprint

Non-Small Cell Lung Carcinoma
Leukemia
Neoplasms
Mediastinoscopy
Tomography
Benchmarking
Lung Diseases
Lung Neoplasms
Radiotherapy
Lymph Nodes
Biopsy
Drug Therapy

ASJC Scopus subject areas

  • Oncology

Cite this

D'Cunha, J., Herndon, J. E., Herzan, D. L., Patterson, G. A., Kohman, L. J., Harpole, D. H., ... Kratzke, R. A. (2005). Poor correspondence between clinical and pathologic staging in stage 1 non-small cell lung cancer: Results from CALGB 9761, a prospective trial. Lung Cancer, 48(2), 241-246. https://doi.org/10.1016/j.lungcan.2004.11.006

Poor correspondence between clinical and pathologic staging in stage 1 non-small cell lung cancer : Results from CALGB 9761, a prospective trial. / D'Cunha, Jonathan; Herndon, James E.; Herzan, Debra L.; Patterson, G. Alexander; Kohman, Leslie J.; Harpole, David H.; Kernstine, Kemp H.; Kern, Jeffrey A.; Green, Mark R.; Maddaus, Michael A.; Kratzke, Robert A.

In: Lung Cancer, Vol. 48, No. 2, 05.2005, p. 241-246.

Research output: Contribution to journalArticle

D'Cunha, J, Herndon, JE, Herzan, DL, Patterson, GA, Kohman, LJ, Harpole, DH, Kernstine, KH, Kern, JA, Green, MR, Maddaus, MA & Kratzke, RA 2005, 'Poor correspondence between clinical and pathologic staging in stage 1 non-small cell lung cancer: Results from CALGB 9761, a prospective trial', Lung Cancer, vol. 48, no. 2, pp. 241-246. https://doi.org/10.1016/j.lungcan.2004.11.006
D'Cunha, Jonathan ; Herndon, James E. ; Herzan, Debra L. ; Patterson, G. Alexander ; Kohman, Leslie J. ; Harpole, David H. ; Kernstine, Kemp H. ; Kern, Jeffrey A. ; Green, Mark R. ; Maddaus, Michael A. ; Kratzke, Robert A. / Poor correspondence between clinical and pathologic staging in stage 1 non-small cell lung cancer : Results from CALGB 9761, a prospective trial. In: Lung Cancer. 2005 ; Vol. 48, No. 2. pp. 241-246.
@article{937802609316412a8ae122e3ee2a7db1,
title = "Poor correspondence between clinical and pathologic staging in stage 1 non-small cell lung cancer: Results from CALGB 9761, a prospective trial",
abstract = "Purpose: A major problem with the staging system for non-small cell lung cancer (NSCLC) is clinical underestimation of the extent of disease. Many patients with clinical stage 1 disease do not retain that designation following surgical resection. Herein, we present data from Cancer and Leukemia Group B (CALGB) protocol 9761 evaluating the correspondence between clinical and pathologic analysis in early stage NSCLC. Methods: Five hundred and two patients with suspected or biopsy-proven NSCLC classified as clinical stage 1 (T1-2, N0) by computed tomography (CT) scan or cervical mediastinoscopy were prospectively enrolled in CALGB 9761. The purpose of CALGB 9761 was to prospectively evaluate molecular markers of micrometastatic disease in stage 1 NSCLC. Enrollment occurred at 11 selected institutions within the CALGB. Patients with clinically suspected resectable early stage lung cancer were eligible for enrollment if they had no evidence of mediastinal or hilar adenopathy on CT scan or if they had CT evidence of potential N2 or N3 disease (lymph node ≥1.0 cm) but with negative mediastinoscopy. No prior chemotherapy or radiotherapy was permitted. Results: Of the 502 patients felt to have clinical stage 1 NSCLC enrolled in CALGB 9761, 489 underwent resection with complete surgical staging and routine histopathologic analysis. From these 489 patients, only 422 (86.3{\%}) turned out to have pathologically documented NSCLC. Of these 422 patients, 302 (71.6{\%}) had pathologic stage 1 disease (173 stage 1A and 129 stage 1B). Despite clinical assessment of stage 1 disease, 59 (14{\%}) patients had pathologic stage 2 disease, 57 (13.5{\%}) had stage 3 disease, and four (0.9{\%}) patients had stage 4 disease. Of the patients undergoing resection for clinical stage 1 NSCLC, 65 patients did not have NSCLC (44 had benign disease and 21 had malignancies other than NSCLC) and two additional patients had dual synchronous primary NSCLC tumors and were not eligible for the study. Overall, only 61.7{\%} (302 of 489) of patients with suspected stage 1 NSCLC disease retained that stage and diagnosis after complete surgical staging, while 38.3{\%} had an inaccurate pre-operative clinical stage or diagnosis. Conclusions: The results from this prospective trial demonstrate the poor predictive value of current clinical staging techniques in early stage NSCLC. These findings will serve as a benchmark for comparison of future clinical imaging modalities and other tests evaluating early stage NSCLC.",
author = "Jonathan D'Cunha and Herndon, {James E.} and Herzan, {Debra L.} and Patterson, {G. Alexander} and Kohman, {Leslie J.} and Harpole, {David H.} and Kernstine, {Kemp H.} and Kern, {Jeffrey A.} and Green, {Mark R.} and Maddaus, {Michael A.} and Kratzke, {Robert A.}",
year = "2005",
month = "5",
doi = "10.1016/j.lungcan.2004.11.006",
language = "English (US)",
volume = "48",
pages = "241--246",
journal = "Lung Cancer",
issn = "0169-5002",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

TY - JOUR

T1 - Poor correspondence between clinical and pathologic staging in stage 1 non-small cell lung cancer

T2 - Results from CALGB 9761, a prospective trial

AU - D'Cunha, Jonathan

AU - Herndon, James E.

AU - Herzan, Debra L.

AU - Patterson, G. Alexander

AU - Kohman, Leslie J.

AU - Harpole, David H.

AU - Kernstine, Kemp H.

AU - Kern, Jeffrey A.

AU - Green, Mark R.

AU - Maddaus, Michael A.

AU - Kratzke, Robert A.

PY - 2005/5

Y1 - 2005/5

N2 - Purpose: A major problem with the staging system for non-small cell lung cancer (NSCLC) is clinical underestimation of the extent of disease. Many patients with clinical stage 1 disease do not retain that designation following surgical resection. Herein, we present data from Cancer and Leukemia Group B (CALGB) protocol 9761 evaluating the correspondence between clinical and pathologic analysis in early stage NSCLC. Methods: Five hundred and two patients with suspected or biopsy-proven NSCLC classified as clinical stage 1 (T1-2, N0) by computed tomography (CT) scan or cervical mediastinoscopy were prospectively enrolled in CALGB 9761. The purpose of CALGB 9761 was to prospectively evaluate molecular markers of micrometastatic disease in stage 1 NSCLC. Enrollment occurred at 11 selected institutions within the CALGB. Patients with clinically suspected resectable early stage lung cancer were eligible for enrollment if they had no evidence of mediastinal or hilar adenopathy on CT scan or if they had CT evidence of potential N2 or N3 disease (lymph node ≥1.0 cm) but with negative mediastinoscopy. No prior chemotherapy or radiotherapy was permitted. Results: Of the 502 patients felt to have clinical stage 1 NSCLC enrolled in CALGB 9761, 489 underwent resection with complete surgical staging and routine histopathologic analysis. From these 489 patients, only 422 (86.3%) turned out to have pathologically documented NSCLC. Of these 422 patients, 302 (71.6%) had pathologic stage 1 disease (173 stage 1A and 129 stage 1B). Despite clinical assessment of stage 1 disease, 59 (14%) patients had pathologic stage 2 disease, 57 (13.5%) had stage 3 disease, and four (0.9%) patients had stage 4 disease. Of the patients undergoing resection for clinical stage 1 NSCLC, 65 patients did not have NSCLC (44 had benign disease and 21 had malignancies other than NSCLC) and two additional patients had dual synchronous primary NSCLC tumors and were not eligible for the study. Overall, only 61.7% (302 of 489) of patients with suspected stage 1 NSCLC disease retained that stage and diagnosis after complete surgical staging, while 38.3% had an inaccurate pre-operative clinical stage or diagnosis. Conclusions: The results from this prospective trial demonstrate the poor predictive value of current clinical staging techniques in early stage NSCLC. These findings will serve as a benchmark for comparison of future clinical imaging modalities and other tests evaluating early stage NSCLC.

AB - Purpose: A major problem with the staging system for non-small cell lung cancer (NSCLC) is clinical underestimation of the extent of disease. Many patients with clinical stage 1 disease do not retain that designation following surgical resection. Herein, we present data from Cancer and Leukemia Group B (CALGB) protocol 9761 evaluating the correspondence between clinical and pathologic analysis in early stage NSCLC. Methods: Five hundred and two patients with suspected or biopsy-proven NSCLC classified as clinical stage 1 (T1-2, N0) by computed tomography (CT) scan or cervical mediastinoscopy were prospectively enrolled in CALGB 9761. The purpose of CALGB 9761 was to prospectively evaluate molecular markers of micrometastatic disease in stage 1 NSCLC. Enrollment occurred at 11 selected institutions within the CALGB. Patients with clinically suspected resectable early stage lung cancer were eligible for enrollment if they had no evidence of mediastinal or hilar adenopathy on CT scan or if they had CT evidence of potential N2 or N3 disease (lymph node ≥1.0 cm) but with negative mediastinoscopy. No prior chemotherapy or radiotherapy was permitted. Results: Of the 502 patients felt to have clinical stage 1 NSCLC enrolled in CALGB 9761, 489 underwent resection with complete surgical staging and routine histopathologic analysis. From these 489 patients, only 422 (86.3%) turned out to have pathologically documented NSCLC. Of these 422 patients, 302 (71.6%) had pathologic stage 1 disease (173 stage 1A and 129 stage 1B). Despite clinical assessment of stage 1 disease, 59 (14%) patients had pathologic stage 2 disease, 57 (13.5%) had stage 3 disease, and four (0.9%) patients had stage 4 disease. Of the patients undergoing resection for clinical stage 1 NSCLC, 65 patients did not have NSCLC (44 had benign disease and 21 had malignancies other than NSCLC) and two additional patients had dual synchronous primary NSCLC tumors and were not eligible for the study. Overall, only 61.7% (302 of 489) of patients with suspected stage 1 NSCLC disease retained that stage and diagnosis after complete surgical staging, while 38.3% had an inaccurate pre-operative clinical stage or diagnosis. Conclusions: The results from this prospective trial demonstrate the poor predictive value of current clinical staging techniques in early stage NSCLC. These findings will serve as a benchmark for comparison of future clinical imaging modalities and other tests evaluating early stage NSCLC.

UR - http://www.scopus.com/inward/record.url?scp=20144388892&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=20144388892&partnerID=8YFLogxK

U2 - 10.1016/j.lungcan.2004.11.006

DO - 10.1016/j.lungcan.2004.11.006

M3 - Article

VL - 48

SP - 241

EP - 246

JO - Lung Cancer

JF - Lung Cancer

SN - 0169-5002

IS - 2

ER -